AUTHORS
Kaleigh Ducas-Mowchun, MD, Rena J Buckstein, MD, FRCPC2, Grace Christou3, Annette Hay, MBChB4, Philippe Giguere, MD5, Mohamed Elemary, MD,MSc,PhD,FRCP6, Mary Lynn Savoie, MD, FRCPC7, Tom Dunne, MD, MSc8, Michael Radford, MD, BSc9, Mitchell Sabloff, MSc, MDCM, FRCPC10, Sahar Khan, MB BCh BAO11, Amy M. Trottier, MD, MSc, FRCPC12, Lee Mozessohn, MD13, Michelle Nadine Geddes, MD14, Ryan Zarychanski, MD, MSc, FRCPC15, Brett Houston, MD, PhD16
AFFILIATIONS
1 Cancercare Manitoba, Winnipeg, Manitoba, Canada, University of Manitoba, Winnipeg, Manitoba, Canada
2 Sunnybrook Cancer Centre, Toronto, Ontario, Canada, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
3 The Ottawa Hospital, Ottawa, Ontario, Canada
4 Queen's University, Kingston, Ontario, Canada
5 University of Ottawa, Ottawa, Ontario, Canada
6 Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada
7 Foothills Medical Centre, Calgary, Alberta, Canada
8 Newfoundland & Labrador Health Services, St. John's, Newfoundland, Canada
9 McMaster University, Hamilton, Ontario, Canada
10 The Ottawa Hospital, Ottawa, Ontario, Canada, University of Ottawa, Ottawa, Ontario, Canada
11 Western University, London, Ontario, Canada
12 Dalhousie University, Halifax, Nova Scotia, Canada
13 Sunnybrook Cancer Centre, Toronto, Ontario, Canada, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
14 Foothills Medical Centre, Calgary, Alberta, Canada, University of Calgary, Calgary, Alberta, Canada
15 Cancercare Manitoba, Winnipeg, Manitoba, Canada, University of Manitoba, Winnipeg, Manitoba, Canada
16 Cancercare Manitoba, Winnipeg, Manitoba, Canada, University of Manitoba, Winnipeg, Manitoba, Canada
ABSTRACT
Introduction
Frailty is common among older adults with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) and is associated with reduced treatment tolerance and survival. Although hypomethylating agent (HMA)-based therapy is the standard treatment for many older patients with higher risk MDS and AML, there is limited evidence to guide treatment modification in frailty. We conducted a national survey to characterize contemporary frailty assessment practices and empiric HMA dose modification strategies among Canadian hematologists.
Methods
An electronic survey was distributed to all hematologists affiliated with a Canadian university. Physicians who reported treating older adults with HMA-based therapy completed questions regarding frailty assessment, the influence of frailty on treatment decisions, empiric dose reduction practices, and equipoise for future clinical trials. Descriptive statistics are reported. Percentages are reported based on the number of respondents to each survey question.
Results
Of 60 respondents, 34 (57%) reported treating older adults with MDS or AML with HMA-based therapy and completed the full survey. The majority practiced in academic/tertiary care settings (n=28, 85%) across 6 Canadian provinces.
76% (n=26) of respondents reported that frailty moderately to very much influenced their treatment decisions. Most respondents (n=19, 56%) assessed frailty routinely prior to initiating HMA-based therapy. Clinical gestalt (n=26, 79%) and informal questioning about activities of daily living (n=25, 76%) were the predominant frailty assessment methods, and validated frailty assessment tools were rarely used. The most cited barriers to integrating validated frailty assessment tools were time constraints (n=31, 91%) and limited resources (n=25, 74%).
For MDS, the most common initial regimen used for all comers was azacitidine 75 mg/m² × 7 days every 28 days (n=28, 90%), followed by decitabine/cedazuridine 35 mg/100 mg daily x 5 days every 28 days (n=15, 48%). In the context of frailty, 52% (n=16) sometimes and 48% (n=15) rarely or never implemented empiric dose reductions from cycle 1. The preferred dose reduction strategies were reducing azacitidine days per cycle (n=12, 50%) or reducing decitabine/cedazuridine days per cycle (n=15, 63%), followed by extending treatment interval (n=8, 33%).
For AML, the most common initial regimen used for all comers was azacitidine 75 mg/m² × 7 days plus venetoclax 400 mg daily for 28 days (n=21, 64%). Only respondents treating AML reported always implementing empiric dose reduction for frailty from cycle 1 (n=11, 33%). The preferred dose reduction strategy for AML was reducing venetoclax days per cycle (n=23, 92%).
In AML, the most frequently cited factors prompting dose reduction were poor performance status with ECOG >2 (n=25, 100%), functional dependence (n=25, 100%), comorbidities (n=22, 88%) and frailty as assessed by clinical judgment (n=22, 88%). A similar pattern was observed for MDS. Most respondents (n=26, 77%) reported that disease risk category in MDS or AML did not influence their decision to dose reduce.
The majority of respondents (n=32, 97%) cited limited evidence on frailty-guided dose modifications as a knowledge gap. Most respondents (n=27, 79%) endorsed the need for a clinical trial evaluating the impact of frailty on HMA-based treatment and 62% (n=21) supported a trial evaluating frailty-guided empiric dose modification. Only 6% reported high confidence in their current approach to frailty-informed HMA prescribing.
Conclusions
Canadian hematologists recognize frailty as an important factor in HMA-based treatment decisions for older adults with MDS and AML, yet frailty assessment remains largely informal and based on clinical gestalt. While preliminary, these data suggest variation in the threshold for empiric HMA dose modification in frail patients, with lower threshold for dose modification in AML compared to MDS. The majority of respondents identified frailty-guided dose modification as an evidence gap, and most endorsed the need for a prospective clinical trial. These findings support the development of standardized frailty assessment and evidence-based dose modification strategies to optimize outcomes in this population.
DISCLOSURES
Kaleigh Ducas-Mowchun, MD: No relevant conflicts of interest to declare.